Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret them. Tarsus is a commercial-stage biopharmaceutical company focused on therapeutics starting with eye care, led by XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis and a lotilaner-based pipeline that includes TP-04 and TP-05.
Through this page, users can access Tarsus’ current and historical filings, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe the company’s business, risk factors, financial statements, and discussion of results. Current reports on Form 8-K provide details on material events such as quarterly financial results, annual meeting outcomes, and other significant corporate developments. For example, recent 8-K filings reference press releases that set forth Tarsus’ results of operations for specific quarters and describe shareholder voting results at the annual meeting.
Investors can also review proxy statements referenced in 8-K filings to understand proposals submitted to stockholders, including director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. In addition, Form 4 insider transaction reports, when available, can be used to track purchases and sales of TARS shares by directors, officers, and other insiders.
Stock Titan’s AI features summarize lengthy filings, highlight key sections related to revenue dependence on XDEMVY, pipeline development, capital needs, and risk factors, and explain technical language in more accessible terms. Real-time updates from EDGAR ensure that new Tarsus filings, from 10-K and 10-Q reports to 8-K current reports and Form 4 insider filings, appear promptly so users can follow changes in the company’s regulatory and financial profile without manually parsing every document.
Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals (TARS), reported sales of common stock on 08/11/2025 as shown on this Form 4. The filing lists dispositions of 53,635 and 6,000 shares and shows a transaction price of $50 where indicated, with reported beneficial ownership of 818,106 shares following the transactions. The sales were effected automatically under a Rule 10b5-1 trading plan adopted December 12, 2024. Azamian is trustee of the Bobak Azamian Living Trust (established April 16, 2018) and has voting and dispositive power over the trust shares. The Form 4 was signed by an attorney-in-fact on 08/13/2025.
Tarsus Pharmaceuticals filed a Form 144 reporting a proposed sale of 6,000 shares of common stock through Merrill Lynch in Newport Beach with an aggregate market value of $300,000. The filing lists 42,214,106 shares outstanding and an approximate sale date of 08/11/2025. The shares were acquired on 01/13/2017 in a private placement from Tarsus Pharmaceuticals and were paid for in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.